Rare Disease Clinical Trials - Are They Measuring the Right Things?

Erika Augustine, MD

Erika Augustine, MD, of the University of Rochester talks about the need to have a dialog with the key players in the rare disease community (patients, clinicians, pharmaceutical companies, FDA) on what outcome measures are most appropriate in clinical trials involving rare diseases. 
Printer Printing...